Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma

Histopathology

Volumn 34, Issue 5, 1999, Pages 432-438

  Murono, S ^a,c   Yoshizaki, T ^a   Park, C S ^b   Furukawa, M ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Chonnam National University Medical School   (South Korea)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bcl 2 protein; Epstein Barr virus; Immunohistochemistry; In situ hybridization; Nasopharyngeal carcinoma; p53 protein

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFECTIOUS MONONUCLEOSIS; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0033029244     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00625.x     Document Type: Article

References (34)

1. 1. Harabuchi Y, Yamanaka N, Kataura A et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990; 335; 128-130.
2. 2. Old LJ, Boyse EA, Oettgen HF et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc. Natl. Acad. Sci. USA 1996; 56; 1699-1704.
3. 3. Zur Hausen H. Schulte-Holthausen H, Klein G et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970; 228; 1056-1058.
4. 4. Huang DP, Ho JHC, Henle W et al. Demonstration of Epstein-Barr virus-associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies. Int. J. Cancer 1974; 14; 580-588.
5. 5. Riiab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47; 883-889.
6. 6. Murono S, Yoshizaki T, Tanaka S et al. Detection of Epstein-Barr virus in nasopharyngeal carcinoma by in situ hybridization and polymerase chain reaction. Laryngoscope 1997; 107; 523-526.
7. 7. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278; 261-263.
8. 8. Bodner MS, Minna JD, Jensen SM et al. Expression of mutant proteins in lung cancer collerates with the class of p53 gene mutation. Oncogene 1992; 7; 743-749.
9. 9. Tsujimoto Y, Cossman J, Jafee E et al. Involvement of the bel-2 gene in human follicular lymphoma. Science 1985; 228; 1440-1443.
10. 10. Hockenbery D, Nunez G, Milliman C et al. Bel-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348; 334-336.
11. 11. Pezzella F, Tse AGD, Cordell JL et al. Expression of the hd-2 oncogene protein is not specific for the 14;18 chromosomal translation. Am. J. Pathol. 1990; 137; 225-232.
12. 12. Park CS, Manahan LJ, Brigati DJ. Automated molecular pathology: One hour in situ DNA hybridisation. J. Histotechnol. 1991; 16; 219-229.
13. 13. Young LS, Rowe M. Epstein Barr virus, lymphomas and Hodgkin's disease. Semin. Cancer Biol. 1992; 3; 273-284.
14. 14. Raab-Traub N, Flynn K, Pearson G et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int. J. Cancer 1987; 39; 25-29.
15. 15. Pathmanathan R, Prasad U, Chandrika G et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Am. J. Pathol. 1995; 146; 1355-1367.
16. 16. Akao I, Sato Y, Mukai K et al. Detection of Epstein-Barr virus DNA in formalin-fixed paraffin-embedded tissue of nasopharyngeal carcinoma using polymerase chain reaction and in situ hybridization. Laryngoscope 1991; 101; 279-283.
17. 17. Nicdobitek G, Agathanggelou A, Barber P et al. p53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J. Pathol. 1993; 170; 457-461.
18. 18. Dictor M, Siven M, Tennvall J et al. Determination of nonendemic nasopharyngeal carcinoma by in situ hybridization for Epstein Barr virus EBER1 RNA. Sensitivity and specificity in cervical node metastases. Laryngoscope 1995; 105; 407-412.
19. 19. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344; 777-780.
20. 20. Chang F. Syrjanen S, Tervahauta A et al. Tumourigenesis associated with the p53 tumour suppressor gene. Br. J. Cancer 1993; 68; 653-661.
21. 21. Porter MJ, Field JK, Lee JCK et al. Detection of the tumour suppressor gene p53 in nasopharyngeal carcinoma in Hong Kong Chinese. Anticancer Res. 1994; 14; 1357-1360.
22. 22. Gulley MI, Burton MP, Alfred DC et al. Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Hum. Pathol. 1998; 29; 252-259.
23. 21. Effert P, Mccoy R, Abdel-Hamid M et al. Alterations of the p53 gene in nasopharyngeal carcinoma. J. Virol. 1992; 66; 3768-3775.
24. 24. Spruck III CH, Tsai YC, Huang DP et al. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res. 1992; 52; 4787-4790.
25. 25. Sun Y, Hegamyer G, Cheng YJ et al. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. USA 1992; 89; 6516-6520.
26. 26. Nasrin N, Taiba K, Hannan N et al. Molecular study of EBV DNA and p53 mutations in nasopharyngeal carcinoma of Saudi Arab patients. Cancer Lett. 1994; 82; 189-198.
27. 27. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the inductin of the A20 gene. J. Virol. 1996; 70; 8653-8659.
28. 28. Zhang Q, Gutsch D, Kenny S. Functional and physical interaction between p53 and BZLF1: Implications for Epstein Barr virus latency. Mol. Cell. Biol. 1994; 14; 1929-1938.
29. 29. Sista ND, Pagano JS, Liao W et al. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc. Natl. Acad. Sci. USA 1993; 90; 3894-3898.
30. 30. Gutsch DE, Holley-Guthrie EA, Zhang Q et al. The bzIP transactivator of Epstein Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kB. Mol. Cell. Biol. 1994; 14; 1939-48.
31. 31. Henderson S, Rowe M, Gregory C et al. Induction of bel-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65; 1107-1115.
32. 32. Khan G, Gupta RK. Coates PJ et al. Epstein-Barr virus infection and bcl-2 proto-oncogene expression. Am. J. Pathol. 1993; 143; 1270-1274.
33. 33. Lu QL, Elia G, Lucas S et al. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int. J. Cancer 1993; 53; 29-35.
34. 34. Sheu LF, Chen A, Meng CL et al. Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia, and nasopharyngeal carcinoma: association with p53 expression. Hum. Pathol. 1997; 28; 556-562.